Current and emerging therapies in metastatic pancreatic cancer

Clinical Cancer Research

Volumn 23, Issue 7, 2017, Pages 1670-1678

  Manji, Gulam Abbas ^a   Olive, Kenneth P ^a   Saenger, Yvonne M ^a   Oberstein, Paul ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BMS 936559; CETUXIMAB; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR4; COLONY STIMULATING FACTOR 1; DURVALUMAB; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GANITUMAB; GEMCITABINE; IPILIMUMAB; IRINOTECAN; IRINOTECAN SUCROSOFATE; ISTIRATUMAB; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIVOLUMAB; OLAPARIB; OXALIPLATIN; PEGPH 20; PEMBROLIZUMAB; PLX 3397; RECOMBINANT HYALURONIDASE; ULOCUPLUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CD3+ T LYMPHOCYTE; CELL INFILTRATION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; EXTRACELLULAR MATRIX; FATIGUE; FUNCTIONAL STATUS; GENE THERAPY; HUMAN; MACROPHAGE FUNCTION; MACROPHAGE INFILTRATION; MAINTENANCE THERAPY; MONOTHERAPY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; SENSORY NEUROPATHY; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; VENOUS THROMBOEMBOLISM; ADENOCARCINOMA; GENETICS; IMMUNOTHERAPY; METASTASIS; PANCREAS CARCINOMA; PATHOLOGY; PERSONALIZED MEDICINE; SECOND CANCER;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; NEOPLASM METASTASIS; NEOPLASMS, SECOND PRIMARY; PRECISION MEDICINE; TUMOR MICROENVIRONMENT;

EID: 85017014594     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-2319     Document Type: Article

References (75)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
2. Rahib L, Smith B, Aizenberg R, Rosenzweig AB, Flreshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913-21.
3. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;363:1817-25.
4. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703.
5. Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol 2015;12: 319-34.
6. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefitwith gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
7. Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol 2013;6:321-37.
8. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern cooperative oncology group trial E2297. J Clin Oncol 2002;20: 3270-5.
9. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss group for clinical cancer research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212-7.
10. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27:5513-8.
11. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-16.
12. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27:3778-85.
13. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-52.
14. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Carteni G, Massidda B, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010;28: 1645-51.
15. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
16. Rajeshkumar NV, Yabuuchi S, Pai SG, Tong Z, Hou S, Bateman S, et al. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. Br J Cancer 2016;115:442-53.
17. Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, et al. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol 2016;7:469-78.
18. Metges JP, Ramee JF, Douillard J-Y, Boucher E, Faroux R, Guerin-Meyer V, et al. Efficacy and safety of FOLFIRINOX in patients with metastatic pancreatic cancer. J Clin Oncol 32, 2014 (suppl 3; abstr 305).
19. Mahaseth H, Brutcher E, Kauh J, Hawk N, Kim S, Chen Z, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas 2013;42:1311-5.
20. Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Staugaard C, et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer 2016;114:737-43.
21. Marsh Rde, Talamonti M, Katz M, Herman JM. Pancreatic cancer and FOLFIRINOX: a new era and new questions. Cancer Med 2015;4:853-63.
22. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dorken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase IIIstudy from the German CONKO-study group. Eur JCancer 2011;47:1676-81.
23. Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Secondline oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014;32:2423-9.
24. Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009;101:1658-63.
25. Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, et al. PANCREOX: a randomized phase III study of 5-fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. JClin Oncol 2016 Sep 12. [Epub ahead of print].
26. Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016;387:545-57.
27. Vincent P, Caio RL, Vaibhav S, Simeone D, Ocean A, Phillip P, et al. Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1/2 study. Ann Oncol 2016;27:ii83-4.
28. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest Oncology Group-Directed Intergroup Trial S0205. J Clin Oncol 2010;28:3605-10.
29. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28: 3617-22.
30. Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res 2012;18:40-50.
31. Fuchs CS, Azevedo S, Okusaka T, Van Laethem JL, Lipton LR, Riess H, et al.A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. Ann Oncol 2015;26:921-7.
32. Fitzgerald JB, Johnson BW, Baum J, Adams S, Ladevaia S, Tang J, et al.MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther 2014;13:410-25.
33. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
34. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28.
35. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al.MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558-62.
36. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010;33:828-33.
37. Brahmer JR, Tykoddi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;28;366:2455-65.
38. Khalil DN, Segal NH. Modern immunotherapy for the treatment of advance gastrointestinal cancers. Oncology 2016;30:85-90.
39. Le DT, Uram JN, Wang H, Kemberling H, Eyring A, Bartlett B, et al. PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. J Clin Oncol 34, 2016 (suppl 4S; abstr 195).
40. Johnson BA 3rd, Yarchoan M, Lee V, Laheru DA, Jaffee EM. Strategies for increasing pancreatic tumor immunogenicity. Clin Cancer Res 2017;23: 1656-69.
41. Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 2013;110:20212-7.
42. Tavor S, Weiss I, Beider K, Wald H, Eizenberg O, Pereg Y, et al. The CXCR4 antagonist BL-8040 efficiently induces apoptosis and inhibits the survival of AML cells. Blood 2013;122:3939.
43. Eriksson E, Wenthe J, Irenaeus S, Loskog A, Ullenhag G. Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer. J Transl Med 2016;14:282.
44. Shibuya KC, Goel VK, Xiong W, Sham JG, Pollack SM, Leahy AM, et al. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. PLoS One 2014;9:e96565.
45. Plate JM, Plate AE, Shott S, Bograd S, Harris JE. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 2015;54:915-25.
46. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004;4:528-39.
47. Cheng XB, Sato N, Kohi S, Yamaguchi K. Prognostic impact of hyalouronan and its regulator in pancreatic ductal adenocarcinoma. PLoS One 2013;8:e80765.
48. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21:418-29.
49. Olive KP, Jacobetz MA, Davidson CJ. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
50. Hingorani SR, Harris WP, Seery TE, Zheng L, Sigal D, Hendifar AE, et al. Interim results of a randomized phase II study of PEGPH20 added to nabpaclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancer. J Clin Oncol 34, 2016 (suppl 4S; abstr 439).
51. Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007;13:2870-5.
52. Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012;48:1283-92.
53. Ino Y, Yamazaki-Itho R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 2013;108:914-23.
54. Hertzer KM, Donald GW, Hines OJ. CXCR2: a target for pancreatic cancer treatment? Expert Opin Ther Targets 2013;17:667-80.
55. Sandford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res 2013;3404-15.
56. Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumorinfiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 2004;28:e26-31.
57. Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, et al. Targeting tumor-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-center, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol 2016;17:651-62.
58. Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 2014;74:5057-69.
59. Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 2013;73:1128-41.
60. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev 2012;26:1268-86.
61. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363: 1049-57.
62. Weissmueller S, Manchado E, Sabororwski M, Morrish JP 4th, Wagenblast E, Davis CA, et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF Receptor beta signaling. Cell 2014;157, 382-94.
63. Parrales A, Iwakuma T. Targeting oncogenic mutant p53 for cancer therapy. Front Oncol 2015;5:288.
64. Camp ER, Wang C, Little EC, Watson PM, Pirolllo KF, Rait A, et al. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther 2013;20:222-8.
65. Senzer N, Nemunaitis J, Nemunaitis D, Bedell C, Edelman G, Brave M, et al. Phase I study of systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther 2013;21:1096-103.
66. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 2011;108:3406-11.
67. Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol 2015;33:3124-9.
68. Salo-Mullen EE, O'Reilly EM, Kelsen DP, Ashraf AM, Lowery MA, Yu KH, et al. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer 2015;121:4382-8.
69. Borecka M, Zemankova P, Vocka M, Soucek P, Soukupova J, Kleiblova P, et al. Mutation analysis of the PALB2 gene in unselected pancreatic cancer patients in the Czech Republic. Cancer Genet 2016;209:199-204.
70. Lee JM, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1/2 mutationassociated and BRCA-like malignancies. Ann Oncol 2014;25:32-40.
71. Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 2014;111:1132-8.
72. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-92.
73. Melisi D, Ossovskaya V, Zhu C, Rosa R, Ling J, Dougherty PM, et al. Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity. Clin Cancer Res 2009;15:6367-77.
74. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33:244-50.
75. Domchek SM, Hendifar AE, McWilliams RR, Geva R, Epelbaum R, Biankin A, et al.RUCAPANC: an open-label, phase 2 trial of the PARP inhibitor rucaparib inpatients (pts)withpancreatic cancer (PC) anda knowndeleterious germline or somatic BRCA mutation. J Clin Oncol 34, 2016 (suppl; abstr 4110).